Wave, Kyowa Kirin to advance programs after partners bow out: Deals Report

Wave and Kyowa Kirin each vowed to continue development of a pair of programs after their former partners returned rights to molecules for which they had paid nine-figure upfront payments.

Wave Life Sciences Inc. (NASDAQ:WVE) said it would engage with regulatory authorities as GalNAc-conjugated RNA editing oligonucleotide therapy WVE-006 progresses toward more milestones in a what could be a registrational study. The biotech said Monday that GSK plc (LSE:GSK; NYSE:GSK) returned its rights, which it had held under a 2022 deal in which the pharma had committed $170 million up front, and has since added a $20 million milestone payment. The multiprogram agreement around Wave’s platform remains intact...